Dedalus acquires Dosing, a leading SaaS medication safety solutions provider

SECTOR UPDATE - Dedalus Group

Dedalus acquires Dosing, a leading SaaS medication safety solutions provider: investing in clinical content to improve the quality and safety of care.

Dedalus Group, a leading international healthcare software solutions provider has acquired Dosing GmbH, a leading provider of digitised Software-as-aService (SaaS) medication safety solutions. This acquisition extends Dedalus’ portfolio to include specialised solutions to support medical decision-makers and patients along the entire medication process - from therapy recommendation and prescribing to administration and use directions.

Andrea Fiumicelli, CEO of Dedalus Group, said: " Dosing brings solutions and capabilities that are essential for the digital transformation of the healthcare ecosystem - the core of our vision. We believe that clinically relevant content, such as medication safety information, is central to ensuring the highest quality and safety of care through the Clinical Decision Support (CDS) solutions within our portfolio." 

Michael Dahlweid, Chief Product Officer for Dedalus Group further commented: “We are really excited to bring Dosing into our organisation. Their solutions provide sophisticated and complex medication capabilities that are characterised both by their scope and expertise. Following this acquisition, we are aware of our obligations to Dosing's partners and will ensure that Dosing will continue to work and cooperate with all of them."

Winfried Post, DACH General Manager and member of Dedalus Executive Committee, added: "Today, Dosing’s solutions are being used successfully in more than 270 hospitals, mainly in Germany. This acquisition is an important step to complement our content provider offering in Germany, Austria and Switzerland."

Jens Kaltschmidt, CEO of Dosing, said: "We develop state-of-the-art software to enable safe medication processes. For us, 'Ease of use' is as important as data quality and accurate process integration. Globally recognised academic institutions support us, and our team of experts works hand in hand with renowned business partners. What drives us is the safety and well-being of each and every patient." 

Dedalus is owned by the largest European private equity firm Ardian.

In the acquisition Dedalus has been assisted by KPMG for the accounting diligence, Mazars for the tax diligence, Giovanni & Associati and Loeschner Legal for the legal assistance.

About Dedalus
Founded in Florence in 1982 by the current Chairman Giorgio Moretti, Dedalus is the leading healthcare and diagnostic software provider in Europe and one of the largest in the world. The shareholding structure ensures stability and great financial capacity through the presence of Ardian, the largest private investment company in Europe and the fourth largest in the world.

Since 2016, Dedalus has accelerated its expansion strategy by targeting the growing demand for innovative and comprehensive ICT and Clinical transformation solutions. With the acquisition of Agfa Healthcare IT, Dedalus consolidated its leadership as pan-European player in the healthcare software industry, with a leading position in Hospital IT (HCIS) and Diagnostic (DIS) in Germany, Italy and France. In April 2021 Dedalus completed the acquisition of DXC’s healthcare IT business, continuing its growth journey. Today Dedalus has a strong footprint in UK and Ireland, Northern Europe, Austria, Switzerland, Spain, China, Brazil, Australia, New Zealand and several locations in Latin America, the Middle East and Africa, having a presence in over 40 different countries. Thanks to its undisputed cutting-edge portfolio of leading, new generation solutions, Dedalus covers the whole spectrum of needs for healthcare operators, supporting over 6,000 hospitals and 5,000 laboratories around the world.

www.dedalus.com
www.dedalusgroup.de

About Dosing
Dosing GMBH is the leading provider of SaaS enabling medication safety solutions in hospital as well as patient-centric care services in Germany. The company builds on proprietary digital drug catalogs including exclusive medication safety information and complementary media, enabling more specific therapy recommendations with an installed base in over 270 German hospitals. Dosing builds on an exclusive partnership with a world-renowned research university securing access to best-in-class pharmacological knowhow– developed by health professionals for health professionals.

www.dosing-gmbh.de

About Ardian
Ardian is a world-leading private investment house with assets of US$112bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base. Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world. Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 700 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of around 1.000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.

www.ardian.com

Source: Dedalus Group media release

Sector updates are provided by organisations to eHealthNews.nz and have not necessarily been edited or checked for accuracy. Any queries should be directed to the organisation issuing the release.

Do you have an item to add to sector updates?

Email your information to us at updates@hinz.org.nz

Return to eHealthNews.nz home page